Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Anagrelide may cause a range of side effects during use.What side effects may An···【more】
Release date：2026-01-30Recommended：39
Anagrelide is used to reduce the platelet count in patients with myeloproliferat···【more】
Release date：2026-01-30Recommended：39
Revumenib (Revuforj) is an oral, first-in-class targeted Menin protein inhibitor···【more】
Release date：2026-01-29Recommended：67
Revumenib (trade name: Revuforj) is an oral, first-in-class targeted Menin inhib···【more】
Release date：2026-01-29Recommended：67
Revumenib (trade name: Revuforj) is an oral targeted drug of the Menin inhibitor···【more】
Release date：2026-01-29Recommended：61
Revuforj carries a risk of differentiation syndrome, and patients and their fami···【more】
Release date：2026-01-29Recommended：65
Rivimeinib is available in three tablet strengths: 25 mg, 110 mg, and 160 mg.Wha···【more】
Release date：2026-01-28Recommended：56
Combination of this class of drugs with Revuforj is not recommended; if co-admin···【more】
Release date：2026-01-28Recommended：58
Remission is the primary treatment goal for acute myeloid leukemia (AML) and acu···【more】
Release date：2026-01-28Recommended：60
Administration of rivoceranib is continued until disease progression, occurrence···【more】
Release date：2026-01-28Recommended：63
The recommended dosage of Revuforj varies according to the patient's body we···【more】
Release date：2026-01-28Recommended：59
Take Revuforj exactly as directed by your healthcare provider. Do not change you···【more】
Release date：2026-01-28Recommended：68
